BV6 is primarily used in research related to cancer therapy, particularly in studies focusing on apoptosis induction in cancer cells. It functions as a small-molecule antagonist of inhibitor of apoptosis proteins (IAPs), which are often overexpressed in various cancers, contributing to tumor survival and resistance to treatment. By inhibiting IAPs, BV6 promotes programmed cell death in malignant cells, making it a valuable tool in preclinical studies aimed at developing novel anticancer strategies. Additionally, BV6 is utilized in combination therapies to enhance the effectiveness of other anticancer agents, such as chemotherapeutics or radiation, by overcoming resistance mechanisms. Its role in modulating cell death pathways also extends to investigations in inflammatory diseases and immune responses, where IAPs play a regulatory role. Overall, BV6 serves as a critical compound in advancing understanding and treatment of cancer and related conditions.